Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease : experience from the Phase 3 ATTRACT study

Visualizar/abrir
Data
2019
Autor
Tipo
URI
http://hdl.handle.net/10183/200996
Assunto
Contido em
American journal of medical genetics. Part A. Hoboken, N.J. : Wiley-Blackwell. Vol. 179A (2019), p. 1069–1073
Origem
Estrangeiro
Coleções
 
   

Este item está licenciado na Creative Commons License